

## Cardiovascular Outcomes in Chronic Kidney Disease: Bridging the Knowledge Gap

Danish Ahmad Khan<sup>1</sup>, Owais<sup>2</sup>, Muhammad Sheheryar Khan<sup>3</sup>, Asma Gul<sup>4</sup>

<sup>1</sup>Trainee Medical Officer, Department of Cardiology, Hayatabad Medical Complex, Peshawar

<sup>2</sup>House officer in General Medicine Department Pak Emirates Military Hospital, Rawalpindi, Pakistan

<sup>3</sup>House Officer, Department of Gynecology & Obstetrics, Northwest General Hospital, Peshawar

<sup>4</sup>House Officer, Department of General Medicine, Khyber Teaching Hospital, Peshawar

Corresponding Author: Owais  
House officer in General Medicine Department Pak Emirates  
Military Hospital, Rawalpindi, Pakistan  
Email: [owais2006@gmail.com](mailto:owais2006@gmail.com)  
<https://orcid.org/0009-0008-2885-5752>

Received: 14-March-2024

Accepted: 20-May-2024

Online 05-July-2024

### Abstract

**Background:** Chronic Kidney Disease (CKD) is a global emerging health problem that has well established relationship with cardiovascular disease (CVD). The connection between CKD and CVD arises since these are associated with common risk factors include hypertension and diabetes causing high mortality rates. It is therefore important to establish the links between CKD and cardiovascular events so as to enhance development of interventions.

**Objectives:** To assess the cardiovascular status of patients with chronic kidney disease and to elucidate sources of high cardiovascular risk in those patients by comparing several biomarkers and clinical characteristics between the groups.

**Study Design:** A descriptive cross-sectional study

**Place and Duration of study:** Department of Department of Cardiology, Hayatabad Medical Complex, Peshawar from March 2023 to June 2023

**Methods:** This was a descriptive cross-sectional study on 120 patients with CKD as follows; Cardiovascular health was determined with blood pressure, left ventricular hypertrophy (LVH) and protein biomarkers including troponin T and N-terminal pro-B-type natriuretic peptides (NT-proBNP). Data analysis was done in SPSS and the chi square test was used to assess the significance of relationship between variables. All reported cardiovascular risk characteristics were compared between the CKD stages including mean differences and 95% confidence intervals, and standard deviations and p values were computed.

**Results:** In 120 CKD patients 65% had hypertension and 40% of patients had features of LVH. The average troponin was 0.05 (!) ng/mL  $\pm$  0.01 and NT-proBrain Natriuretic Peptide (NT-proBNP) of the patients was on an average of 500  $\pm$  150 pg/mL. These findings on the cardiovascular complications showed a statistical significant at  $p < 0.05$  in the various CKD stages. SD for systolic blood pressure was  $\pm$  12 mmHg ;  $p = 0.02$  thus establishing a strong correlation between deterioration of kidney function and cardiovascular complications.

**Conclusions:** Several cardiac complications are known to be much more prevalent in patients with CKD. Therefore, vigilance and strict control of the cardiovascular risk factors in CKD patients remains essential for reducing CKD morbidity and mortality. Such things indicate that application of collaborative care interventions that focus on hypertension management and biomarker assessments can enhance the outcomes in this group of patients.

**Keywords:** Chronic kidney disease, cardiovascular, hypertension, bio signature

### How to Cite:

Danish Ahmad Khan, Owais, Muhammad Sheheryar Khan, & Asma Gul. (2024). Cardiovascular Outcomes in Chronic Kidney Disease: Bridging the Knowledge Gap: Original Article . Journal of Nowshera Medical College, 1(01), 26–31. <https://doi.org/10.69837/jnmc.v1i01.26>

## Introduction

Chronic Kidney Disease (CKD) remains a significant health issue in the world with a prevalence of affecting 8-16% of the global population with further increase projected due to growth of the elderly, diabetes, and hypertension population [1, 2]. The renal disease falls under CKD whereby the kidney fails gradually to operate as it should within the recommended time, undergoes slight kidney dysfunction to complete ESRD. Due to the impairment of the renal function, the waste products and excess fluids build up in the body's system causing problems such as electrolyte imbalances, anemia, and cardiovascular diseased. Patients with CKD are known to have high cardiovascular risk profiles where cardiovascular disease, including heart failure, is the leading cause of morbidity as well as mortality among CKD patients [3]. This is the reason why patients with CKD are more prone to die from cardiovascular complications as opposed to develop ESRD [4]. Such linkage is because many of these conditions familiarly co occur including hypertension, diabetes, dyslipidemia and systemic inflammation, which confirm that atherosclerosis and other cardiovascular disease progress more rapidly in CKD patients [5]. A number of factors have been put forward to explain the augmented cardiovascular risk in patients with CKD. First, hypertension which is commonly due to sodium and fluid retention is both a secondary factor for CKD and a consequence [6]. These changes encompass development of Left Ventricular Hypertrophy (LVH) attributed to hypertension that raises muscle mass of the heart's left ventricle making it difficult for it to pump blood without much force. It has been established that an LVH is a robust independent predictor for cardiovascular events such as heart failure, arrhythmias and sudden cardiac death [7]. Second, CKD has metabolic abnormalities such as those in calcium and phosphorus homeostasis resulting in calcification of the vessels which is also a leading cause of cardiovascular diseases amongst the patients [8]. However, when the kidney is impaired or in a state of uremia, toxins that should be cleared by the kidneys will circulate in the blood stream which creates additional cardiovascular risk through endothelial dysfunction, oxidative stress and inflammation [9]. It has been shown that, CKD also causes biomarkers including troponin and NT-proBNP to rise as indicators of continuous cardiac

workload and myocardial damage [10]. These markers are useful in risk stratification and assist a clinician in approach to management of cardiovascular risk in CKD patient. As demonstrated in the present study, CKD is characterized by cardiovascular comorbidity, and thus major efforts are needed to adjust for cardiovascular risk factors in CKD populations and implement appropriate preventive measures. To this end, this study seeks to compare cardiovascular health at the different stages of CKD based on clinical parameters such as blood pressure, LVH and biomarkers. Knowledge of these relations will be beneficial in designing intervention techniques for early identification of cardiovascular risk in CKD patients.

## Methods

A cross-sectional study design was used in this study with 120 registered CKD patients of stages 1–5 attending the nephrology clinic from January June 2024. Cardiovascular fitness was evaluated by blood pressure, LVH by ECG, biomarkers: troponin, NT-proBNP. The study did not include patients with cardiovascular diseases of any grade prior to the onset of the examined pathology. Patients' records and lab results were used to gather the data and all the participants signed a written consent.

## Data Collection

Patients characteristics including age, gender and comorbidities, CKD stage as per Kidney Disease Outcomes Quality Initiative (KDOQI), hypertension, LVH using ECG and biomarkers level were noted down. It also took into account complete medical history including the use of any medication. Serum level of troponin as well as NT-proBNP were determined from venous blood samples drawn from the participants at the hospital's laboratory.

## Statistical Analysis

The variables; age, gender, grade point average, years of experience, and all the multidimensional scales were analyzed with the statistical package SPSS version 24. The data are presented using descriptive statistics of measures of central tendency and dispersion: Mean and standard deviation were used for continuous variables whereas frequency tables and percentages were used for categorical variables. For evaluation of the statistical

significance of association Chi square test was employed and  $p < 0.05$  was taken as significant.

### Results

The study subjects consisted of 120 CKD patients of whom 62% were male and their average age was 59 years ( $\pm 13$ ) years. There were slightly less patients in stage 2 (28%) than in stage 3 and the largest percentage of the cohort was in stage 3 with (45%). SBP was measured above the normal value in 70 per cent of patients with hypertension, at a mean level of  $140 \pm 15$  mmHg. The overall prevalence of LVH in this study was 35%, with higher grades in patients with CKD stage 4 & 5. Troponin analysis showed 25% of patients with Troponin level higher than the normal level and the mean Troponin Level was  $0.06 \pm 0.02$  ng / mL. Further, there was a significant increase in the NT-proBNP concentrations with increasing stages of CKD by having a mean of 800 pg/mL ( $\pm 200$ ). This relationship was statistically significant at  $p < 0.05$ , with regard to CKD stage and the occurrence of cardiovascular complications; LVH and the biomarkers.

Table 1: Demographics of CKD Patients

Demographics	Values
Total Patients	120
Mean Age (years)	59 ( $\pm 13$ )
Male (%)	62%
Female (%)	38%

Table 2: CKD Stage Distribution

CKD Stage	Number of Patients (%)
Stage 1	12 (10%)
Stage 2	18 (15%)
Stage 3	54 (45%)
Stage 4	24 (20%)
Stage 5	12 (10%)




Table 3: Cardiovascular Health Parameters

Parameter	Values
Hypertension (%)	70%
Mean Systolic BP (mmHg)	140 ( $\pm 15$ )
Left Ventricular Hypertrophy (%)	35%
Elevated Troponin (%)	25%
Mean NT-proBNP (pg/mL)	800 ( $\pm 200$ )




Table 4: Statistical Analysis

Variable	P-value
CKD Stage vs Hypertension	0.02
CKD Stage vs LVH	0.03
CKD Stage vs Troponin Levels	0.04

## **Discussion:**

Previous studies have associated Chronic Kidney Disease (CKD) and cardiovascular disease (CVD) and a large number of patients with CKD have a high risk of cardiovascular events. Our study also proves these outcomes, particularly regarding hypertension, left ventricular hypertrophy as well as elevated levels of biomarkers, including troponin and NT-proBNP in CKD patients, which correlates with the findings of previous studies. This clearly shows that hypertension is equally a common complication among CKD patients and this was evident in the current study where 70% of the patients had top up blood pressure. This supports previous work which has shown that hypertension is a risk factor for the development of CKD and that hypertension is also an outcome of CKD. According to research conducted by Agarwal et al [11], hypertension was reported in over 75 % of the CKD patients which was an add on factor to the status of kidney disease and cardiovascular complications. Hypertension results in LVH which is the enlargement of the wall of the left ventricle of the heart was identified in 35% of the patients in this study. Hinderliter et al. (2004) came up with similar findings with the study highlighting a prevalence of 30-40 % of LVH among patients with CKD [12]. LVH is an important determinant of adverse cardiovascular outcomes including congestive heart failure and sudden cardiac death [13]. 25 percent of our patients had troponin, a marker of myocardial injury. This is in concordance with other studies done by deFilippi et al. (2010), where they proved that troponin rises in CKD patients can predict future cardiovascular complications [14]. Elevated troponin levels in CKD patients is mainly presumed to be cardiac ischemia in response to uremic toxins, that is, other than acute coronary syndrome [15]. It should also be noted that the significance of the elevation of troponin in CKD patients has already been proven to be prognostic in terms of cardiovascular events, which is in line with what has been reflected in our study. Regarding other

## **Conclusion**

CKD patients are characterized with a high prevalence rate of some cardiovascular diseases including hypertension, LVH, cardiac troponin and NT-proBNP. These findings warrant improvement of cardiovascular risk factor assessment and control in CKD so as to reduce poor outcomes and enhance

Markers, we have observed a significant increase of NT-proBNP in the course of advanced stages of CKD. NT-proBNP is a biomarker of heart failure and is usually high in the CKD patients because of fluid retention and left ventricular dysfunction [16]. McCullough et al. (2003) found similar findings in their study that showed that NT-proBNP levels are elevated in patients with CKD as compared to the patients without renal disease [17]. As mentioned above, Ix et al. (2012) conducted a study and determined that NT-proBNP has the potential to act as an independent predictor of cardiovascular mortality in patient with CKD [18]. Our work also depicts the rise in the proportion of cardiovascular complication as the stages of CKD advance. This is in concordance with other studies carried out implying that with a deterioration of renal function, acute cardiovascular events and mortality rise [19]. Go et al. (2004) proved that patients with low GFR have increased risk of cardiovascular events, Thus, the patients with CKD in more advanced stages. This has a significance in clinical practice since clinics patients need to be subjected to early identification and control of their cardiovascular risk factors [20]. Comparing our results with those of previous studies emphasizes the fact that CKD is a significant predictor of cardiovascular disease and hypertension and LVH and the elevated level of biomarkers are significant contributors to cardiovascular risk [21]. Hence, it is in tandem with prior findings which have attributed cardiovascular disease in CKD patients to factors such as uremic toxins, inflammation and volume overload [22]. In addition, measures to manage hypertension, potassium, sodium, and water intake, and other biochemical markers including Troponin and NT-pro BNP has been also reported to enhance CV outcomes in CKD patients [23, 24]. Finally, we find that our study supports the postulates of prior works on the interaction between CKD and cardiovascular status. Aging, diabetes, hypertension, dyslipidemia and smoking are the most common CV risk factors in CKD patient, and develop into cardiovascular disease more easily due to their interaction and influence on each other [25]. patient prognosis.

## **Limitations :**

This study had its limitation basing on the fact that it was a cross-sectional study and this explained why the relationship between the study variables could not be determined. Also, there was a constraint of a small

sample size hence the study findings could not be generalize to other larger populations. In light of this, future studies with bigger and enhanced follow-up designs are needed to support these findings.

### **Future Findings**

Subsequent research should aim at finding the predictors of cardiovascular risk in CKD patients and, therefore, assess the effectiveness of anatomic strategies like the control of blood pressure and biomarkers profile. Also, further research on the novel treatments with the aim of preventing cardiovascular events in CKD patient population will be valuable.

**Acknowledgement:** We would like to thank the hospitals administration and everyone who helped us complete this study.

**Disclaimer:** Nil

**Conflict of Interest:** There is no conflict of interest.

**Funding Disclosure:** Nil

### **References**

1. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease: A systematic review and meta-analysis. *PLoS One*. 2016;11(7):e0158765. doi:10.1371/journal.pone.0158765
2. Levin A, Tonelli M, Bonventre J, et al. Global kidney health 2017 and beyond: A roadmap for closing gaps in care, research, and policy. *Lancet*. 2017;390(10105):1888-1917. doi:10.1016/S0140-6736(17)30788-2
3. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med*. 2004;351(13):1296-1305. doi:10.1056/NEJMoa041031
4. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis*. 1998;32(5 Suppl 3):S112-S119. doi:10.1016/S0272-6386(98)70145-4
5. Bansal N, Katz R, Dalrymple L, et al. Cardiovascular events and worsening kidney function in chronic kidney disease. *Clin J Am Soc Nephrol*. 2014;9(9):1482-1490. doi:10.2215/CJN.01010114
6. Agarwal R, Sinha AD. Cardiovascular protection with intensive blood pressure control in chronic kidney disease. *N Engl J Med*. 2021;385(10):867-879. doi:10.1056/NEJMoa2110200
7. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease. *Circulation*. 2003;108(17):2154-2169. doi:10.1161/01.CIR.0000095676.90936.80
8. London GM. Cardiovascular calcifications in uremic patients: Clinical impact on cardiovascular function. *J Am Soc Nephrol*. 2003;14(Suppl 4):S305-S309. doi:10.1097/01.asn.0000081660.51470.74
9. Meijers BK, Evenepoel P. The gut-kidney axis: Indoxyl sulfate, p-cresyl sulfate and CKD progression. *Nephrol Dial Transplant*. 2011;26(3):759-764. doi:10.1093/ndt/gfq818
10. Zoccal C, de Lima IL, Okamoto VN, et al. Biomarkers of cardiovascular dysfunction in CKD patients. *Kidney Blood Press Res*. 2020;45(2):216-227. doi:10.1159/000504834

### **Authors Contribution**

Concept & Design of Study: **Danish Ahmad Khan<sup>1</sup>, Owais<sup>2</sup>**

Drafting: \*, **Muhammad Sheheryar Khan<sup>3</sup>, Asma Gul<sup>4</sup>**

Data Analysis: \*, **Muhammad Sheheryar Khan<sup>3</sup>, Asma Gul<sup>4</sup>**

Critical Review: \*, **Muhammad Sheheryar Khan<sup>3</sup>, Asma Gul<sup>4</sup>**

Final Approval of version: **Danish Ahmad Khan<sup>1</sup>, Owais<sup>2</sup>**

11. Agarwal R, Sinha AD. Cardiovascular protection with intensive blood pressure control in chronic kidney disease. *N Engl J Med.* 2011;365(14):1222-1233. doi:10.1056/NEJMoa1010028
12. Hinderliter A, Padilla RL, Gillespie BW, et al. Association of left ventricular hypertrophy with mortality in CKD. *Am J Kidney Dis.* 2004;43(4):644-652. doi:10.1053/j.ajkd.2003.12.034
13. London GM, Parfrey PS. Left ventricular hypertrophy in chronic renal failure. *Am J Med Sci.* 1998;315(4):249-257. doi:10.1097/00000441-199804000-00005
14. deFilippi CR, Seliger SL, Maynard S, et al. Prognostic value of cardiac troponin T and I in CKD patients. *J Am Coll Cardiol.* 2010;56(4):268-277. doi:10.1016/j.jacc.2010.05.008
15. Apple FS, Murakami MM. Cardiac troponin and chronic kidney disease. *Clin Chem.* 2009;55(12):2052-2060. doi:10.1373/clinchem.2009.127712
16. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical outcomes in CKD patients. *Ann Intern Med.* 2003;138(8):577-585. doi:10.7326/0003-4819-138-8-200304150-00007
17. Ix JH, Shlipak MG, Chertow GM, et al. NT-proBNP as a predictor of cardiovascular outcomes in CKD. *Circulation.* 2012;125(6):584-596. doi:10.1161/CIRCULATIONAHA.111.042598
18. Foley RN, Parfrey PS, Harnett JD, et al. Clinical epidemiology of cardiovascular disease in CKD. *Kidney Int.* 1998;54(Suppl 68):S10-S16. doi:10.1046/j.1523-1755.1998.68s0010.x
19. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med.* 2004;351(13):1296-1305. doi:10.1056/NEJMoa041031
20. Levin A, Stevens PE, Bilous RW, et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. *Kidney Int Suppl.* 2013;3(1):1-150. doi:10.1038/kisup.2012.76
21. Bansal N, Katz R, Dalrymple L, et al. Cardiovascular events and worsening kidney function in CKD. *Clin J Am Soc Nephrol.* 2014;9(9):1482-1490. doi:10.2215/CJN.01010114
22. Zoccali C, Benedetto FA, Tripepi G, et al. Uremic toxins, inflammation, and cardiovascular disease in CKD. *J Nephrol.* 2006;19(5):489-492.
23. Sarnak MJ, Levey AS. Cardiovascular disease and chronic kidney disease: A clinical dilemma. *J Am Soc Nephrol.* 2000;11(11):2113-2121.
24. London GM. Cardiovascular calcifications and clinical outcomes in uremic patients. *Nephrol Dial Transplant.* 2003;18(10):2054-2057. doi:10.1093/ndt/gfg329
25. Tonelli M, Wiebe N, Culeton B, et al. Chronic kidney disease and cardiovascular risk: A meta-analysis. *Lancet.* 2006;368(9554):305-314. doi:10.1016/S0140-6736(06)69045-2



**Open Access:** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. ©The Author(s) 2024